B. Riley reiterated their buy rating on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Thursday morning, MarketBeat.com reports. B. Riley currently has a $5.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $10.00. B. Riley also issued estimates for Evoke Pharma’s FY2022 earnings at $1.40 EPS.
EVOK has been the topic of a number of other research reports. Zacks Investment Research upgraded Evoke Pharma from a sell rating to a hold rating in a research report on Monday, November 20th. ValuEngine downgraded Evoke Pharma from a sell rating to a strong sell rating in a research report on Friday, December 1st. Finally, HC Wainwright restated a buy rating and set a $9.00 price target on shares of Evoke Pharma in a research report on Tuesday, March 6th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $7.66.
Shares of Evoke Pharma (NASDAQ:EVOK) opened at $1.98 on Thursday. Evoke Pharma has a 12-month low of $1.85 and a 12-month high of $4.09.
Several large investors have recently made changes to their positions in EVOK. Deutsche Bank AG bought a new position in shares of Evoke Pharma during the fourth quarter valued at about $452,000. Sphera Funds Management LTD. grew its stake in shares of Evoke Pharma by 34.7% during the fourth quarter. Sphera Funds Management LTD. now owns 769,149 shares of the specialty pharmaceutical company’s stock valued at $1,738,000 after buying an additional 198,127 shares during the last quarter. 683 Capital Management LLC bought a new position in shares of Evoke Pharma during the fourth quarter valued at about $258,000. B. Riley Financial Inc. bought a new position in shares of Evoke Pharma during the fourth quarter valued at about $249,000. Finally, Creative Planning bought a new position in shares of Evoke Pharma during the fourth quarter valued at about $226,000. 18.71% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3257354/evoke-pharma-evok-receives-buy-rating-from-b-riley.html.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.